Everest Medicines Acquires Exclusive Rights to VIS-101 for Eye Disorders
Everest Medicines has acquired an exclusive license to develop, manufacture, and commercialize VIS-101, a novel bifunctional biologic for serious eye disorders, in Greater China, Singapore, South Korea, and certain Southeast Asian countries.
The company has partnered with Visara, Inc., a subsidiary of NovaBridge Biosciences, to secure this exclusive license, marking Everest's expansion into ophthalmology, a high-potential therapeutic area.
- Upfront payment: US$7 million (approximately RMB49.7 million)
- Reimbursement for prior expenses: up to RMB24.0 million
- Potential future payments: up to US$89 million
No additional quotes are provided in the text.
Author's summary: Everest Medicines expands into ophthalmology with VIS-101 license.
More News
- Republicans lose ground in Tennessee special election
- This Tranquil Florida State Park
- No. 1 Kentucky breezes by Wofford in round 1 of the NCAA Tournament
- Breeze’s David Neeleman: Why Startup Airlines Can’t Compete With the Big Four
- Teleperformance Shares Advance 3.39% at Opening
- Ground News – Largest News Aggregator
- FGR manager Robbie Savage focus of new BBC documentary
- Suryakumar Yadav Breaks Past Rohit Sharma to Set New Mumbai T20 Batting Record
- Suryakumar Yadav Becomes Mumbai's Highest T20 Run-Scorer